JUVÉDERM VOLUMA XC For Temple Hollows Receives U.S. FDA Approval
Portfolio Pulse from Benzinga Newsdesk
Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the U.S. FDA approval of JUVÉDERM VOLUMA XC for temple hollowing improvement in adults. This marks the first FDA approval for a hyaluronic acid dermal filler in the upper face, addressing a significant unmet need. Clinical studies showed over 80% improvement in temple hollowing three months post-treatment, with results lasting up to 13 months. The approval underscores Allergan Aesthetics' commitment to innovation and patient care.
March 05, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie's subsidiary, Allergan Aesthetics, received FDA approval for JUVÉDERM VOLUMA XC for temple hollowing, marking a significant advancement in dermal fillers.
The FDA approval of JUVÉDERM VOLUMA XC for temple hollowing represents a significant milestone for AbbVie's Allergan Aesthetics, highlighting its commitment to innovation and addressing unmet patient needs. This approval could enhance AbbVie's reputation in the aesthetics market and potentially boost its financial performance by expanding its product portfolio with a unique offering. Given the positive clinical trial results and the product's unique positioning, there is a strong likelihood of positive short-term impact on AbbVie's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100